Equities

Novacyt SA

NCYT:LSE

Novacyt SA

Health CareMedical Equipment and Services
  • Price (GBX)34.45
  • Today's Change-0.15 / -0.43%
  • Shares traded27.79k
  • 1 Year change-31.65%
  • Beta0.1827
Data delayed at least 20 minutes, as of Feb 06 2026 14:23 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Novacyt SA is a France-based company providing biotechnological solutions. The Company develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. It provides diagnostic products used in oncology, microbiology, haematology, and serology testing. The Company develops secure automated cytology named NovaPrep Processor System. It offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. It creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle.

  • Revenue in EUR (TTM)22.00m
  • Net income in EUR-31.97m
  • Incorporated2006
  • Employees234.00
  • Location
    Novacyt SA131 Boulevard Carnot, Le VesinetVELIZY VILLACOUBLAY 78110FranceFRA
  • Phone+33 139465104Fax+33 130700532
  • Websitehttps://novacyt.com/fr
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.